• Tempus AI had 37 abstracts accepted for presentation at the 2026 ASCO Annual Meeting, its largest scientific showing at this conference.
• The work centers on the company’s multimodal data platform and AI driven insights in cancer care.
• The volume of accepted research highlights growing interest from the oncology research community in Tempus AI’s technology.

Tempus AI (NasdaqGS:TEM) is drawing attention not just for its technology, but for how often that technology is now showing up in high profile clinical research. The stock recently closed at $46.66 and is up 2.5% over the past week, although it is down 10.5% over the past month and down 25.2% year to date. Over the past year, the share price is down 29.2%, reflecting a period in which the market has not rewarded the stock despite this expanding research footprint.

For investors, the 37 ASCO abstracts point to deeper integration of Tempus AI’s platform into real world oncology studies. This can be an important signal when assessing the role of its tools in precision medicine. As more data emerges from these projects, you will be able to track whether research traction translates into broader clinical and commercial use, and whether that begins to shift sentiment around NasdaqGS:TEM.

Stay updated on the most important news stories for Tempus AI by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Tempus AI.

The record presence at ASCO lines up with Tempus AI’s push to turn its multimodal data into products that sit directly in clinical workflows. The recent clinical launch of the ArteraAI Prostate Test for metastatic hormone sensitive prostate cancer shows how that can look in practice, giving clinicians a CLIA certified, AI powered digital pathology tool that plugs into the existing Tempus platform. For investors, the link between ASCO exposure and products like ArteraAI is important, because it suggests the research activity you see at conferences may feed into tests that can be ordered as add ons across the solid tumor portfolio. At the same time, the expanded Bristol Myers Squibb collaboration in oncology and Alzheimer’s clinical trials indicates that Tempus AI is also trying to monetize its data on the biopharma side, not just through diagnostics. Competitors such as Guardant Health, Exact Sciences and Flatiron Health are also active around AI and real world oncology data, so the scale and quality of Tempus AI’s research output and product uptake will be key markers of how differentiated its platform really is.

How This Fits Into The Tempus AI Narrative

• The ASCO presence and ArteraAI Prostate Test launch both support the narrative that Tempus AI can turn its multimodal data and biopharma partnerships into widely used clinical tools and recurring data revenue.
• The focus on AI driven diagnostics also highlights the narrative risk that reimbursement and regulatory clarity for algorithms may take time, which could slow monetization even if clinical interest is high.
• The first externally developed algorithm offered through the platform, ArteraAI, introduces a partner distribution angle that is not fully captured in narratives focused mainly on Tempus AI’s own assays and data backlog.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Tempus AI to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Tempus AI remains unprofitable and analysts do not currently forecast profitability over the next three years, so there is execution risk if revenue growth or cost control do not track expectations.
• ⚠️ Reimbursement and regulatory frameworks for AI based and digital pathology tests are still evolving, which could delay or limit revenue from tools like the ArteraAI Prostate Test.
• 🎁 The company is trading at a discount to one independent fair value estimate, and revenue is forecast to grow 16.43% per year, which some investors may see as a potential reward if execution stays on track.
• 🎁 Large scale partnerships with groups such as Bristol Myers Squibb, plus the ability to host third party algorithms on the Tempus platform, point to multiple ways to use the multimodal data asset across diagnostics and biopharma.

What To Watch Going Forward

From here, it will be useful to track how many of the ASCO featured projects progress into clinically available tests or new data partnerships, and whether clinicians meaningfully adopt the ArteraAI Prostate Test as an add on to Tempus AI’s solid tumor offering. Pay attention to updates on reimbursement and regulatory status for AI powered diagnostics, because that will influence how quickly conference visibility and partnerships turn into revenue, especially against competition from players such as Guardant Health and Exact Sciences. Investors may also want to watch whether Tempus AI discloses metrics around test ordering volumes, partner algorithms onboarded to the platform and the scale of its real world data collaborations, as these can provide tangible signals on how the product and data ecosystem is developing.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Tempus AI, head to the community page for Tempus AI to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.